Full Breakdown
FDA Staff Challenge Capricor’s Duchenne Therapy Claims Ahead of Advisory Committee
7/28/2026, 12:02:15 PM
Core Event: FDA reviewers dispute Phase 3 results for deramiocel
- On July 27, 2026, FDA staff released briefing documents stating that the Phase 3 HOPE-3 trial of Capricor Therapeutics’ cell therapy deramiocel failed to achieve its pre-specified primary and secondary efficacy endpoints for Duchenne muscular dystrophy (DMD). Reviewers noted no statistically significant difference between deramiocel and placebo on upper-limb function (PUL 2.0) or left-ventricular ejection fraction at 12 months.
Background & Context
- Capricor announced in December 2025 that deramiocel met both primary and secondary endpoints in the HOPE-3 trial, a result that would have marked a rare efficacy signal in DMD, a disease lacking approved cardiomyopathy therapies. The company subsequently filed a biologics license application (BLA) and scheduled an FDA advisory committee meeting for July 29, 2026.
Data & Statistics
- FDA reviewers reported that the HOPE-3 primary endpoint change in PUL 2.0 “did not reach statistical significance.”
- Cardiac imaging showed “small and variable changes” without significant improvement in left-ventricular ejection fraction (LVEF).
- Adverse-event imbalance: hypersensitivity reactions occurred in 42 % of deramiocel-treated patients versus 15 % of placebo, raising concerns about functional unblinding.
- Capricor’s share price fell between 61 % and 65 % after the briefing, trading around $6.53–$7.66 per share.
Official Statements & Responses
- Capricor’s position: CEO Linda Marbán asserted that the final analysis plan (SAP version 3.0) was finalized before unblinding and that the HOPE-3 results demonstrate a statistically significant benefit on the primary endpoint and supportive cardiac effects. She emphasized the company’s “full and transparent” engagement with the FDA.
- FDA staff assessment: Reviewers said that converting raw change to percent change and back “is not scientifically justified” and that the post-hoc SAP version 1.1 used in the briefing was an unsigned, incomplete draft not agreed to by the agency. They also highlighted the lack of a clear treatment effect and potential unblinding.
Criticism & Opposition
- FDA staff questioned the methodological changes made after trial completion, including redefining endpoint metrics and altering the statistical analysis plan. They argued that these revisions undermine confidence in the efficacy signal.
- Reviewers also noted that the trial population had near-normal cardiac function at baseline, limiting the ability to demonstrate a meaningful cardiomyopathy benefit.
Conflicting Reports & Gaps
- Share-price reporting: Reuters-based coverage noted a 65 % drop to $6.53, while Benzinga reported a 61.12 % decline to $7.66. Both figures reflect the same market reaction but differ in magnitude and price level.
- Statistical analysis plan: Capricor maintains that SAP version 3.0 governed the results; FDA staff focus on SAP version 1.1, an internal draft the agency did not approve. The discrepancy leaves unclear which analysis the agency will consider at the July 29 adcomm.
What’s Next
- An FDA advisory committee meeting is scheduled for July 29, 2026, where independent experts will review the BLA and the FDA’s concerns. The outcome will determine whether deramiocel proceeds toward potential approval or faces further regulatory setbacks.
